利福喷丁抗菌谱广, 对结核杆菌(包括结核丝杆菌、鸟分枝杆菌、非结核分枝杆菌、麻风杆菌等)、革兰氏阳性菌、革兰氏阴性菌、沙眼衣原体、鼠弓形体等有很强的活性, 而且对链霉素、异烟肼和利福平耐药菌株亦有效,对临床上难治的鸟分枝杆菌和胞内分枝杆菌复合菌株也有抑制作用, 同时对某些病毒有抑制作用。与利福平相比, 已耐利福平的分枝杆菌对利福喷丁无完全性叉耐药性, 30%的利福平耐药结核分枝杆菌对利福喷丁仍然敏感; 而且, 利福喷丁可以迅速进入多型核白细胞并在其中保持较高的浓度, 而且由于其良好的脂溶性和较长的半衰期而具有长效作用, 因此利福喷丁在治疗结核包括利福平耐药菌株所致结核和防治MAC(鸟胞内分枝杆菌复合菌株)感染上有优势 深圳翻译公司。
The antibacterial spectrum of Rifapentine is wide and it has very potent activity on Bacillus tuberculosis (including Sphaerophorus tuberculosis, Mycobacterium avium, nontuberculoaus mycobacteriosis, Bacillus leprae and others), Gram-positive bacteria, Gram-negative bacteria, Bedsonia trachomatis, Toxoplasma gondii and other bacteria, and it is also effects for streptomycin-, isoniazide-, rifampin- and other drug resistant strains. It has inhibitory effects on clinically refractory compound stains of Mycobacterium avium and Mycobacterium intracellulare, and it can also inhibit some viruses. In comparison to rifampin, rifampin-resistant Mycobacterium do not show complete cross tolerance to Rifapentine, and 30% of the rifampin-resistant mycobacterium tuberculosis are still sensitive to Rifapentine; furthermore, Rifapentine can rapidly enter polymorphonuclear leucocytes and maintain at a relatively high concentration, and it has long-term effects due to its excellent liposolubility and relatively long half life, therefore, Rifapentine has its advantages in the treatment on tuberculosis (including tuberculosis induced by rifampin resistant stains) as well as prevention and treatment on MAC (Mycobacterium avium complex) infection.
基于国内结核病的流行趋势及可供选择的抗结核药尤其是对于耐多药结核有效的品种仍然非常有限的现实状况, 根据在国外应用利福喷丁治疗耐多药肺结核的临床实践, 设计了以治疗耐多药肺结核为适应症的随机、对照、多中心的临床研究方案, 旨在评价利福喷丁治疗耐多药肺结核的有效性和安全性。于2002年6月在全国七家结核病医院同时展开了为期18个月的临床研究 上海日语翻译。 Based on the prevailing tendency of tuberculosis in our country and the practical situation that anti-tuberculosis drugs for choice are still very limited, particularly the effective varieties for multi-drug resistant pulmonary tuberculosis, we designed the random, control and multicenter clinical research program with multi-drug resistant pulmonary tuberculosis as the indication according to the clinical practices by using Rifapentine in treating multi-drug resistant pulmonary tuberculosis in foreign countries in order to evaluate the effectiveness and safety of Rifapentine in treating multi-drug resistant pulmonary tuberculosis. The clinical investigations for 18 months were simultaneously carried out in seven tuberculosis hospitals all over the country in June 2002. |
|
|
|
|
注：1、上述翻译行业适用于笔译和口译服务，而笔译类别则专指公司可处理的笔译文
件。
2、如需了解详细信息，请点击相应的行业或来电来函与公司取得联系。
3、相关翻译报价请单击顶部的翻译价格体系查看。 |
